Зміст
Добірка наукової літератури з теми "Mouth Cancer South Australia Statistics"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Mouth Cancer South Australia Statistics".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Mouth Cancer South Australia Statistics"
1
Tallis, G. M., P. Leppard, and T. J. O'Neill. "The effect on survival of early detection of breast cancer in South Australia." Model Assisted Statistics and Applications 1, no. 2 (July 14, 2006): 115–23. http://dx.doi.org/10.3233/mas-2005-1208.
Повний текст джерела
2
Malalasekera, Ashanya, Prunella L. Blinman, Haryana M. Dhillon, Natalie A. Stefanic, Peter Grimison, Ankit Jain, Mario D’Souza, Steven C. Kao, and Janette L. Vardy. "Times to Diagnosis and Treatment of Lung Cancer in New South Wales, Australia: A Multicenter, Medicare Data Linkage Study." Journal of Oncology Practice 14, no. 10 (October 2018): e621-e630. http://dx.doi.org/10.1200/jop.18.00125.
Повний текст джерелаАнотація:
Introduction: Earlier access to lung cancer specialist (LCS) care improves survival. We examined times to diagnosis and treatment of patients with lung cancer in rural and metropolitan New South Wales (NSW) Australia, benchmarked against recent timeframe recommendations. Materials and Methods: Semistructured interviews of recently diagnosed patients with lung cancer from five NSW cancer centers were used to determine standardized time intervals to diagnosis and treatment, triangulated with Medicare data linkage and medical records. We used descriptive statistics to evaluate the primary end points of median time intervals from general practitioner (GP) referral to first LCS visit (GP-LCS interval) and to treatment start (Secondary Care interval). Univariable and multivariable analyses were used to study associations with delays in end points. Post hoc survival analyses were performed. Results: Data linkage was performed for 125 patients (68% stage IV; 69% metropolitan), with 108 interviewed. The median GP-LCS interval was 4 days, with 83% of patients seeing an LCS within the recommended 14 days. The median Secondary Care interval was 42 days (52% within 42 days). There were no significant differences between time intervals faced by rural and metropolitan patients overall, although metropolitan patients took 18 days less than rural counterparts to commence radiation/chemoradiation (95% CI, −33.2 to −2.54; P = .02). One third of patients perceived delays. Delays did not affect survival. Conclusion: Rural and metropolitan NSW patients face comparable time lines to diagnosis and treatment of lung cancer. Most patients are seen by an LCS within recommended timeframes, but transition through Secondary Care and addressing patient expectations could be improved.
3
Green, Anna, Natalia Jerzmanowska, Safrina Thristiawati, Marguerite Green, and Elizabeth A. Lobb. "Culturally and linguistically diverse palliative care patients’ journeys at the end-of-life." Palliative and Supportive Care 17, no. 2 (June 4, 2018): 227–33. http://dx.doi.org/10.1017/s1478951518000147.
Повний текст джерелаАнотація:
AbstractObjectiveTo understand the clinical and psychosocial journey of culturally and linguistically diverse (CALD) palliative care patients.MethodThis study was conducted at a subacute hospital with a specialist palliative care unit and a community palliative care service in a metropolitan region of New South Wales, Australia. Medical records of 100 deceased patients from CALD backgrounds over a 12-month period from 2014 to 2015 were recorded on a data mining tool. The cohort had transitioned to either community or inpatient palliative care services with a life-limiting illness. We used descriptive statistical analyses to identify the patients’ end-of-life journeys in the physical, psychological, spiritual, and social palliative care domains. Staff case notes were used to enrich the quantitative data.ResultThe most common symptoms burdening the patients were decreased mobility (82%), pain (76%), and poor appetite (60%). The majority of patients (87%) were diagnosed with cancer. Language was a major barrier to the assessment and management of symptoms. The vast majority of patients were born in Europe and Asia. Twenty-nine percent of the patients preferred to use English. However, among patients who required an interpreter on admission, only 9% used professional interpreters. Family distress around patients’ lack of food consumption was prominent, along with provider concern when this led to families “force feeding” patients. Only 5% of files documented patients’, and 21% of files documented families’, cultural wishes or needs. Care of the body after death was only documented in 20% of files.Significance of resultsThe increasing cohort of older people from CALD backgrounds will have significant implications for the planning and delivery of palliative care services. There is an emerging need to address the physical, psychological, spiritual, and social palliative care domains in the end-of-life journeys of patients from CALD backgrounds to ensure the provision of quality care.
4
Razali, K., J. Amin, GJ Dore, MG Law, and HCV Projections Working Group. "Modelling and calibration of the hepatitis C epidemic in Australia." Statistical Methods in Medical Research 18, no. 3 (November 26, 2008): 253–70. http://dx.doi.org/10.1177/0962280208094689.
Повний текст джерелаАнотація:
Hepatitis C virus (HCV) infection in Australia is predominantly transmitted through injecting drug use. A reduction in the heroin supply in Australia in late 2000 and early 2001 may have impacted the number of injecting drug users (IDUs) and the number of new hepatitis C infections. This paper updates estimates of HCV incidence between 1960 and 2005 and models long-term sequelae from infection. Outcomes among those with HCV were also recently assessed in a linkage study assessing cancer and causes of death following HCV diagnosis in New South Wales. Linkage study outcomes have been used here to calibrate modelled outcomes. Mathematical models were used to estimate HCV incidence among IDUs, migrants to Australia from high HCV-prevalence countries, and other HCV exposure groups. Recent trends in numbers of IDUs were based on indicators of injecting drug use. A natural history of HCV model was applied to estimate the prevalence of HCV in the population. Model predicted endpoints that were calibrated against the NSW linkage data over the period 1995—2002 were: (i) incident hepatocellular carcinoma (HCC); (ii) opioid overdose deaths; (iii) liver-related deaths; and (iv) all-cause mortality. Modelled estimates and the linkage data show reasonably good calibration for HCC cases and all-cause mortality. The estimated HCC incidence was increased from 70 cases in 1995 to 100 cases in 2002. All-cause mortality estimated at 1000 in 1995 increased to 1600 in 2002. Comparison of annual opioid deaths shows some agreement. However, the models underestimate the rate of increase observed between 1995 and 1999 and do not entirely capture the rapid decrease in overdose deaths from 2000 onwards. The linkage data showed a peak of overdose deaths at 430 in 1999 compared to 320 estimated by the models. Comparison of observed liver deaths with the modelled numbers showed poor agreement. A good agreement would require an increase in liver deaths from the assumed 2 to 5% per annum following cirrhosis in the models. Mathematical models suggest that HCV incidence decreased from a peak of 14,000 infections in 1999 to 9700 infections in 2005, largely attributable to a reduction in injecting drug use. The poor agreement between projected and linked liver deaths could reflect differing coding of causes of deaths, underestimates of the numbers of people with cirrhosis following HCV, or underestimates of rates of liver death following cirrhosis. The reasonably good agreement between most of the modelled estimates with observed linkage data provides some support for the assumptions used in the models.
5
Reeders, Jocelyn, Vivek Ashoka Menon, Anita Mani, and Mathew George. "Clinical Profiles and Survival Outcomes of Patients With Well-Differentiated Neuroendocrine Tumors at a Health Network in New South Wales, Australia: Retrospective Study." JMIR Cancer 5, no. 2 (November 20, 2019): e12849. http://dx.doi.org/10.2196/12849.
Повний текст джерелаАнотація:
Background Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies with varying and often indolent clinicobiological characteristics according to their primary location. NETs can affect any organ and hence present with nonspecific symptoms that can lead to a delay in diagnosis. The incidence of NETs is increasing in Australia; data regarding characteristics of NETs were collected from the cancer registry of Hunter New England, Australia. Objective This study aimed to explore the clinical profiles and treatment and survival outcomes of patients with well-differentiated NETs in an Australian population. Methods We reviewed the data of all adult patients who received the diagnosis of NET between 2008 and 2013. The clinicopathological, treatment, and follow-up data were extracted from the local Cancer Clinical Registry. We also recorded the level of remoteness for each patient by matching the patient’s residential postcode to the corresponding Australian Bureau of Statistics 2011 remoteness area category. Univariate analysis was used to find the factors associated with NET-related mortality. Survival analysis was computed. Results Data from 96 patients were included in the study (men: 37/96, 38.5%, and women: 59/96, 61.5%). The median age at diagnosis was approximately 63 years. A higher proportion of patients lived in remote/rural areas (50/96, 52.1%) compared with those living in city/metropolitan regions (46/96, 47.9%). The most common primary tumor site was the gastroenteropancreatic tract, followed by the lung. The factors significantly associated with NET-related mortality were age, primary tumor site, surgical resection status, tumor grade, and clinical stage of the patient. At 5 years, the overall survival rate was found to be 62%, and the disease-free survival rate was 56.5%. Conclusions Older age, advanced unresectable tumors, evidence of metastasis, and higher-grade tumors were associated with poorer outcomes. Lung tumors had a higher risk of NET-related mortality compared with other sites.
6
Kalu, Kingsley, Angelica Ly, Charles McMonnies, and Jayashree Arcot. "Dietary Lutein, Zeaxanthin and Omega-3- Essential Fatty Acid Intake and Risk of Age-Related Macular Degeneration in a Selected Australian Population." Current Developments in Nutrition 4, Supplement_2 (May 29, 2020): 111. http://dx.doi.org/10.1093/cdn/nzaa041_015.
Повний текст джерелаАнотація:
Abstract Objectives The aim of this study was to assess the dietary intakes of lutein, zeaxanthin (L + Z) and omega-3-essential fatty acid(EFA) among a selected population of Australian based adults and to examine the effect of specified risk factors for age-related macular degeneration(AMD) on those levels. Methods A cross-sectional study involving 70 adults aged 19–52 years was carried out. Demographic data were obtained using an online self-administered questionnaire while dietary intakes were estimated using USDA's 24 hours recall questionnaire, the Victorian Cancer Council(Australia) food frequency questionnaire and anthropometric characteristics were obtained using a body composition analyzer. Dietary intakes of lutein, zeaxanthin, omega-3-EFA and anthropometric indices against the risk of AMD were established using descriptive statistics and Spearman correlation. Results The mean age of the population was 29.9 ± 8.1years with 51% men and 49% women. Women had a higher intake of L + Z (1908.6 μg/day versus 1032.8 μg/day) and alpha-linolenic acid(ALA) compared to men(1.7 ± 1.1 g/day versus 1.6 ± 1.2 g/day). Men consumed more omega-3-EFA than women (433 ± 397.1 mg/day versus 365 ± 210.7 mg/day). L + Z levels were higher among people of Middle Eastern and South Asian origin (>4000 μg/day) in the 19–25years age group. People of Middle Eastern, South East Asian and South Asian had the highest intake of omega-3-EFA(>500 mg/day) at ages 19–25, 26–32 and 34–52years respectively. Women aged 34–52years with a family history of AMD had higher levels of L + Z(>2500 μg/day) while women aged 26–32years with a family history of AMD had higher levels of ALA(>3 g/day). Ethnicity and L + Z were correlated (P = −0.456, P < 0.02). Higher levels of intake of L + Z (>4000 μg/day) were seen in participants aged 34–52years with a 5–10years residence in Australia. Participants who had less than 5–10years of residency had higher levels of omega-3-EFA(>500 mg/day) for ages 26–32years while those aged 34–52years who had less than 5years of residency had higher ALA(>4 g/day). Conclusions Intake levels for L + Z vary significantly among participants. Culturally specific dietary habits could feasibly influence the levels of intake of L + Z. Intake levels of omega-3-EFA were met. This study provides detailed intake levels of L + Z and omega-3-EFA for the ‘at-risk’ AMD group. Funding Sources No funding source.
7
Bulsara, Vishal M., Max K. Bulsara, and Emma Lewis. "Protocol for prospective randomised assessor-blinded pilot study comparing hyperbaric oxygen therapy with PENtoxifylline+TOcopherol± CLOdronate for the management of early osteoradionecrosis of the mandible." BMJ Open 9, no. 3 (March 2019): e026662. http://dx.doi.org/10.1136/bmjopen-2018-026662.
Повний текст джерелаАнотація:
IntroductionOsteoradionecrosis (ORN) of the mandible is a painful and debilitating condition occurring after radiotherapy to the head and neck to treat cancer. For decades, hyperbaric oxygen (HBO) has formed the mainstay of the early management of ORN. Literature about the efficacy of HBO is contentious. Recently, Oral and Maxillofacial surgical units in France and UK have trialled a combination of medications to treat ORN, also known as PENTOCLO (PENtoxifylline+TOcopherol±CLOdronate). This regime has shown promising results to date however randomised controlled trials in the area comparing HBO against PENTOCLO are lacking and there are no current trials registered in Europe, UK, Australia and the USA. The purpose of this pilot study is to generate a hypothesis that can be tested in large multi-centre controlled trials.Methods and analysisFor this pilot study we will recruit 16 patients who will be randomly allocated to one of either HBO or PENTOCLO. After a 4 week period of uniform ‘pre-treatment’ medication patients will be commenced on their allocated treatment. Standard follow-up examination, imaging and photographs will be taken and de-identified and then presented to two Oral and Maxillofacial surgeons for allocation of a Notani & Lyons classification score. Data for each patient will be tracked over the 18 months of treatment and follow-up. The results will then be analysed using descriptive statistics and all patients included in an intention to treat analysis.Ethics and disseminationEthical approval for this study has been granted by the South Metropolitan Health Service HREC (PRN RGS0000001193). Data generated by conducting this study will be uploaded to an open access repository in a de-identified form. Results from this study will be disseminated at national and international conferences as well as peer reviewed medical publications.Trial registration numberACTRN12618001099213; Pre-results.
8
"Bioboard." Asia-Pacific Biotech News 12, no. 07 (May 2008): 5–21. http://dx.doi.org/10.1142/s021903030800044x.
Повний текст джерелаАнотація:
AUSTRALIA – A New Skin Cancer Warning to the Over 60s AUSTRALIA – Joint Venture to Establish up to 12 ATOS Wellness Centers in Australia AUSTRALIA – New South Wales to Allow Cultivation of Genetically Modifed Canola CHINA – Nanodrug for Pig's Foot-and-Mouth Disease CHINA – Project for a Joint Biodiversity Lab in Yunnan Underway CHINA – New Plants for Biofuel INDIA – Texas Instruments — Indian Institute of Technology Pact INDIA – Ranbaxy and Department of Biotechnology Tie-up for R&D INDIA – Ayurvedic Association Agreement with American Herbal Association INDIA – Indo-Dutch Ties Set to Further Advance Agribiotech Research INDIA – Girl Undergoes Surgery in India to Gain Height INDIA – Bioserve to Set up New Facility in Hyderabad with US$2 Million Investment INDIA – Intas is Setting up India's First Plasma Fractionation Facility JAPAN – AnGes Launches Naglazyme in Japan KOREA – Health Institute Finds Needle-free Vaccination Method KOREA – Scientists Find Gene Promoting Liver Cancer Growth MALAYSIA – Dubai Group Invests in Southeast Asia's Largest Biodiesel Plant MALAYSIA – Malaysia on Track to Become Biotech Hub NEW ZEALAND – Blood Donors May Actually Become “Healthier” SINGAPORE – Scientifc Pioneer Davor Solter Joins A*STAR to Nurture Next Generation of Researchers and Clinician-Scientists SINGAPORE – Rockeby and National University of Singapore to Jointly Develop World's First Rapid Diagnostic Test Kit for Hand, Foot and Mouth Disease SINGAPORE – Singaporean Research Team Develops First Cytotoxic Antibody against Undifferentiated Stem Cells SINGAPORE – Singapore is Set to Promote Clinical Research in Public Hospitals SINGAPORE – Singapore Heart Foundation to Raise Awareness of Heart Disease among Women SINGAPORE – New Research Center Gets US$127 Million for Cancer Research SINGAPORE – Wyeth to Expand State-of-the-Art Nutritional Manufacturing Facility in Singapore TAIWAN – Taiwanese Patient Lives without Heart for 16 Days TAIWAN – Joint Canada-Taiwan Biofuel Development Project Announced TAIWAN – Researchers Find New Way to Probe Liver THAILAND – Thai Scientist Cracks Rice Gene
9
Sarich, Peter, Karen Canfell, Sam Egger, Emily Banks, Grace Joshy, Paul Grogan, Valerie Beral, and Marianne Weber. "863Alcohol and cancer in an Australian cohort of 226,162 participants aged 45 years and over." International Journal of Epidemiology 50, Supplement_1 (September 1, 2021). http://dx.doi.org/10.1093/ije/dyab168.581.
Повний текст джерелаАнотація:
Abstract Background Australia has a relatively high level of alcohol consumption. Although alcohol consumption is known to increase the risk of several cancer types internationally, local evidence for Australia is limited. Methods Cox proportional hazards regressions were used to calculate hazard ratios (HR) and 95% confidence intervals (CI) for cancer risk in relation to weekly alcohol consumption among 226,162 participants aged ≥45 years (2006-2009) in the 45 and Up Study, an Australian prospective cohort study. Incident cancer cases were ascertained by linkage to the New South Wales Cancer Registry to December 2013 by the Centre for Health Record Linkage. Results Over a median 5.4 years, 17,332 cancers were diagnosed. Increasing levels of alcohol intake were associated with increased risk of any cancer (HR per seven drink increase in weekly consumption: 1.02; 95% CI: 1.00-1.04), and cancers of the upper aerodigestive tract (1.19;1.10-1.29), mouth/pharynx (1.18;1.08-1.29), oesophagus (1.22;1.04-1.43), colorectum (1.09;1.04-1.15), colon (1.13;1.06-1.20), liver (1.22;1.04-1.44), breast (1.09;1.00-1.18), and melanoma (1.05;1.00-1.10); whereas an inverse association was observed for thyroid cancer (0.80;0.64-1.00). We estimated that by age 85 years, Australian men and women who consume >14 drinks/week increase their absolute risk of alcohol-attributable cancer by 4.4% and 5.4%, respectively, compared to non-drinkers. Conclusions We report relative risks of cancer incidence in relation to alcohol consumption that match the international evidence. In Australia, a nation with relatively high alcohol consumption, these risks may translate into a significant public health burden. Key messages We have generated estimates for the relationship between alcohol consumption and cancer risk in Australia.
10
"INSIDE INDUSTRY." Asia-Pacific Biotech News 21, no. 12 (December 2017): 34–44. http://dx.doi.org/10.1142/s0219030317000866.
Повний текст джерелаАнотація:
Asia-Pacific, the rising region for cancer vaccine clinical trials. Non-small cell lung cancer has largest number of clinical trials in Australia. Global dermatology pipeline to see shift towards increased usage of biologics. FDA approves first 0.1 mg auto-injector for life-threatening allergic reactions in infants and small children. FDA approves first two-drug regimen for certain patients with HIV. New early-breast cancer drug to be made available in Australia, New Zealand and South-East Asia. Multi-omic data analytics collaboration between the University of Oxford and Holmusk. NRGene’s genomic analysis project with Monsanto advances. Samsung BioLogics receives first FDA approval at world’s largest plant. TLC welcomes Mayor of Leiden and delegation to Taipei headquarter. Warren Wang appointed senior vice president and president of Asia Pacific of Boston Scientific. MiRXES reveals globalisation plans for 2018 and 2019. QuintilesIMS is now IQVIA. Quotient Sciences launches as the new global identity for Quotient Clinical. ESMO Asia 2017 Congress. More care is needed for cancer supportive care. ALEX study shows alectinib 600 mg more effective than crizotinib in Asian lung cancer patients. Study analyses mutations in cerebrospinal fluid in lung cancer with brain metastases. Study finds all Myanmar mouth cancer patients chew betel quid.
Дисертації з теми "Mouth Cancer South Australia Statistics"
1
Moore, Simon Reading. "Oral cancer in South Australia : a twenty year study 1977-1996." Title page, table of contents and precis only, 1999. http://web4.library.adelaide.edu.au/theses/09DM/09dmm824.pdf.
Повний текст джерела